Can park some profits of Scomnet & gloves into next GEM, Luster:

10 Apr 2020 Acquired
74,220,000 MR NG NGOON WENG
19 Mar 2020 Acquired
500,000 MR PHUAH CHENG PENG
19 Mar 2020 Acquired
500,000 MR PHUAH CHENG PENG
10 Oct 2019 Acquired
97,550,000 MR CHUAH CHONG EWE
10 Oct 2019 Acquired
97,550,000 MR CHUAH CHONG EWE

Bosses of Penta & Scomnet are there!!!

Can park some profits of Scomnet & gloves into next GEM, Luster:

10 Apr 2020 Acquired
74,220,000 MR NG NGOON WENG
19 Mar 2020 Acquired
500,000 MR PHUAH CHENG PENG
19 Mar 2020 Acquired
500,000 MR PHUAH CHENG PENG
10 Oct 2019 Acquired
97,550,000 MR CHUAH CHONG EWE
10 Oct 2019 Acquired
97,550,000 MR CHUAH CHONG EWE

Bosses of Penta & Scomnet are there!!!

Can park some profits of Scomnet & gloves into next GEM, Luster:

10 Apr 2020 Acquired
74,220,000 MR NG NGOON WENG
19 Mar 2020 Acquired
500,000 MR PHUAH CHENG PENG
19 Mar 2020 Acquired
500,000 MR PHUAH CHENG PENG
10 Oct 2019 Acquired
97,550,000 MR CHUAH CHONG EWE
10 Oct 2019 Acquired
97,550,000 MR CHUAH CHONG EWE

Bosses of Penta & Scomnet are there!!!

Can park some profits of Scomnet & gloves into next GEM, Luster:

10 Apr 2020 Acquired
74,220,000 MR NG NGOON WENG
19 Mar 2020 Acquired
500,000 MR PHUAH CHENG PENG
19 Mar 2020 Acquired
500,000 MR PHUAH CHENG PENG
10 Oct 2019 Acquired
97,550,000 MR CHUAH CHONG EWE
10 Oct 2019 Acquired
97,550,000 MR CHUAH CHONG EWE

Bosses of Penta & Scomnet are there!!!

Can park some profits of Scomnet & gloves into next GEM, Luster:

10 Apr 2020 Acquired
74,220,000 MR NG NGOON WENG
19 Mar 2020 Acquired
500,000 MR PHUAH CHENG PENG
19 Mar 2020 Acquired
500,000 MR PHUAH CHENG PENG
10 Oct 2019 Acquired
97,550,000 MR CHUAH CHONG EWE
10 Oct 2019 Acquired
97,550,000 MR CHUAH CHONG EWE

Bosses of Penta & Scomnet are there!!!

Covid Vacine for Pharma, can park some profits to Pharma.

Covid Vacine for Pharma, can park some profits to Pharma.

Covid Vacine for Pharma, can park some profits to Pharma.

Covid Vacine for Pharma, can park some profits to Pharma.

Covid Vacine for Pharma, can park some profits to Pharma.

Covid Vacine for Pharma, can park some profits to Pharma.

https://www.zaobao.com.sg/realtime/china/story20200713-1068789

https://youtu.be/EHxB3NbqXgo

https://youtu.be/EHxB3NbqXgo

https://youtu.be/EHxB3NbqXgo

https://www.zaobao.com.sg/realtime/china/story20200713-1068789

https://www.zaobao.com.sg/realtime/china/story20200713-1068789

Wau..... excellent

next week RM20 PAT RM1B, QR out

USA:
No stock:
https://www.amazon.in/MULTICOMP-M1090206-NITRILE-BODYGUARD-GLOVES/dp/B...

https://www.amazon.com/s?k=nitrile+glove&ref=nb_sb_noss_1

USD18-20 /100pcs; if 1000 pcs then USD180-200

Malaysia:
https://my.element14.com/multicomp/m1090205/glove-disposable-small-nit...

RM141.71 / 100 pcs; if 1000 pcs then RM1400

U.S. coronavirus cases rise by over 60,000, setting single-day record

https://www.washingtonpost.com/health/2020/07/08/ppe-shortage-masks-gl...

Some hospitals say much of the PPE they have acquired has been exorbitantly priced. At a legislative hearing, a hospital association executive detailed how one Maryland hospital that spent $600,000 on PPE last year expects to spend $10 million this year. The struggles have been especially acute for smaller and rural providers that can’t compete with bigger health systems on price and large-scale orders, experts say.

A hospital spent before covid was jumped from 600k to 10m; its ratio proven that gloves were running off of stocks.

By using this ration, Supermx share price shall multiply by 10-16 time from RM1.8; which is equal to RM 18-28

2021 Jan-Mar, new TP price : RM18-28

PAT RM1B

PAT RM1B

https://www.worldometers.info/coronavirus/country/us/

USA break 61k a day covid cases

https://www.washingtonpost.com/health/2020/07/08/ppe-shortage-masks-gloves-gowns/

Some hospitals say much of the PPE they have acquired has been exorbitantly priced. At a legislative hearing, a hospital association executive detailed how one Maryland hospital that spent $600,000 on PPE last year expects to spend $10 million this year. The struggles have been especially acute for smaller and rural providers that can’t compete with bigger health systems on price and large-scale orders, experts say.

A hospital spent before covid was jumped from 600k to 10m; its ratio proven that gloves were running off of stocks.

By using this ration, Supermx share price shall multiply by 10-16 time from RM1.8; which is equal to RM 18-28

RM1.5 new TP

Demand over supply (example):

USA:
No stock:
https://www.amazon.in/MULTICOMP-M1090206-NITRILE-BODYGUARD-GLOVES/dp/B00DKCCV8O

https://www.amazon.com/s?k=nitrile+glove&ref=nb_sb_noss_1

USD18-20 /100pcs; if 1000 pcs then USD180-200

Malaysia:
https://my.element14.com/multicomp/m1090205/glove-disposable-small-nitrile/dp/2527469?st=personal-protection-hygiene

RM141.71 / 100 pcs; if 1000 pcs then RM1400

Demand over supply (example):

USA:
No stock:
https://www.amazon.in/MULTICOMP-M1090206-NITRILE-BODYGUARD-GLOVES/dp/B00DKCCV8O

https://www.amazon.com/s?k=nitrile+glove&ref=nb_sb_noss_1

USD18-20 /100pcs; if 1000 pcs then USD180-200

Malaysia:
https://my.element14.com/multicomp/m1090205/glove-disposable-small-nitrile/dp/2527469?st=personal-protection-hygiene

RM141.71 / 100 pcs; if 1000 pcs then RM1400

Demand over supply (example):

USA:
No stock:
https://www.amazon.in/MULTICOMP-M1090206-NITRILE-BODYGUARD-GLOVES/dp/B00DKCCV8O

https://www.amazon.com/s?k=nitrile+glove&ref=nb_sb_noss_1

USD18-20 /100pcs; if 1000 pcs then USD180-200

Malaysia:
https://my.element14.com/multicomp/m1090205/glove-disposable-small-nitrile/dp/2527469?st=personal-protection-hygiene

RM141.71 / 100 pcs; if 1000 pcs then RM1400

UOB Report:

https://klse.i3investor.com/servlets/ptres/55937.jsp

fightingdragons dalpinia freetospeak dalpinia UOB REPORT:

FY18: 21.8B pieces per yr

5% OEM, selling at USD80-95

40% OBM thru independent distributor, selling at USD80-160

45% OBM thru own distribution, selling at USD160-170

I count count count, PAT around RM2b per quarter, eps RM1.5 per quarter

Who can calculate based on the facts & figures given by OUB report?

Dalpnia...welcome to the billion-profit-handshaking club...lol..this club was founded bak in may when a group of sifu here found out that supermax profit could run into billion and hand is shaking when calculating. Of course that is in best case scenario and there are too many factors not considered. Since then we only emphasize on conservative projection so that we dun mislead ppl. So lets wait for result n hopeful for a very big profit bonus...l

Please refer to UOB report, then refer to page 3&4, then you got the facts & figures there. Assume the conservative scenario from the ASP, each QR is more than RM1B PAT.

As ASP is pure margin, before Covid all glove average price is around USD20/1000pcs. If Supermx can sell OEM(5%) at USD80-95 then u use USD80, OBM1(40%) at USD 80-160, OBM2(55%) USD160-175.

Conservative take capacity of 20B pieces per annum as per FY18. (Someone said FY20 is 38B pieces per annum)

freetospeak dalpinia UOB REPORT:

FY18: 21.8B pieces per yr

5% OEM, selling at USD80-95

40% OBM thru independent distributor, selling at USD80-160

45% OBM thru own distribution, selling at USD160-170

I count count count, PAT around RM2b per quarter, eps RM1.5 per quarter

Who can calculate based on the facts & figures given by OUB report?

Dalpnia...welcome to the billion-profit-handshaking club...lol..this club was founded bak in may when a group of sifu here found out that supermax profit could run into billion and hand is shaking when calculating. Of course that is in best case scenario and there are too many factors not considered. Since then we only emphasize on conservative projection so that we dun mislead ppl. So lets wait for result n hopeful for a very big profit bonus...lol..

Thanks.

UOB REPORT:

FY18: 21.8B pieces per yr

5% OEM, selling at USD80-95

40% OBM thru independent distributor, selling at USD80-160

45% OBM thru own distribution, selling at USD160-170

I count count count, PAT around RM2b per quarter, eps RM1.5 per quarter

Who can calculate based on the facts & figures given by OUB report?

Pls refer to pg 3&4 of uob report

UOB REPORT:

FY18: 21.8B pieces per yr

5% OEM, selling at USD80-95

40% OBM thru independent distributor, selling at USD80-160

45% OBM thru own distribution, selling at USD160-170

I count count count, PAT around RM2b per quarter, eps RM1.5 per quarter

Who can calculate based on the facts & figures given by OUB report?

https://klse.i3investor.com/servlets/ptres/55932.jsp

Nett Profit RM320-350m = EPS 25cents per Q
4Q= RM1
PE20=RM20
PE30=RM30
PE40=RM40
PE right now 100 = RM100 per share

https://www.worldometers.info/coronavirus/#countries

Next week USA cases may be 100,000 per day as forecast by Dr Fauci:

https://www.today.com/video/dr-fauci-warns-us-could-hit-100-000-new-coronavirus-cases-per-day-it-could-get-very-bad-86605381884

https://www.malaysiawarrants.com.my/marketnews/highlight?cat=todayhighlight&id=6269
Event

MQ Research is reiterating its Outperform (OP) rating on the shares of TOPGLOV and raising its target price to RM30.40, based on a lower target price-earnings (PE) of 23x (was RM20.50 on a target PE of 40x). In MQ Research’s view, the market is underestimating glove makers’ abilities to raise ASPs, and, hence, the potential ASP upside has not been fully priced in. MQ Research’s FY21E profit after tax (PAT) is 108% above consensus’.


Impact

Spot order enquiries on the rise. Management has indicated that enquiries for spot orders from the United States and Europe are on the rise due to the second wave of COVID-19. As such, the company is looking to raise the spot order allocation to more than 20% (vs last two weeks’ guidance of 20%). In MQ Research’s assumptions, it is projecting Top Glove will gradually increase its spot order allocation to 30% from 20% through 2Q FY21E (February 2021).
ASP rise higher than expected. Management has indicated that overall lead time has increased to nearly 15 months from 13–14 months two weeks ago, and the company is seeing higher conversion orders. This should provide Top Glove the power to raise its ASP. The company now plans to increase the ASP for August order deliveries higher than initial guidance of 15%. As such, MQ Research is increasing its FY20E/FY21E/FY22E ASP assumptions 3%/57%/4% to factor in both higher ASP increases and spot order allocation.
Lowering target PE on supernormal FY21E earnings. Based on the aforementioned strategy, MQ Research is projecting that FY21E’s net profit will be triple FY20E net profit. Given MQ Research’s belief that FY21E will be the peak of strong earnings that are unlikely to be repeated in following years, MQ Research is lowering its target price-earnings ratio (PER) to 23x (+0.5 SD) from 40x. To cross check the long-term fair value of the stock, MQ Research uses a discounted cash flow (DCF) methodology to derive a fair value of RM18.70, which translates to 10x FY21E/56x FY22E PERs. MQ Research views gloves as a staple within the healthcare industry and that the shares should trade at a premium multiple long term.

Event

MQ Research is reiterating its Outperform (OP) rating on the shares of TOPGLOV and raising its target price to RM30.40, based on a lower target price-earnings (PE) of 23x (was RM20.50 on a target PE of 40x). In MQ Research’s view, the market is underestimating glove makers’ abilities to raise ASPs, and, hence, the potential ASP upside has not been fully priced in. MQ Research’s FY21E profit after tax (PAT) is 108% above consensus’.


Impact

Spot order enquiries on the rise. Management has indicated that enquiries for spot orders from the United States and Europe are on the rise due to the second wave of COVID-19. As such, the company is looking to raise the spot order allocation to more than 20% (vs last two weeks’ guidance of 20%). In MQ Research’s assumptions, it is projecting Top Glove will gradually increase its spot order allocation to 30% from 20% through 2Q FY21E (February 2021).
ASP rise higher than expected. Management has indicated that overall lead time has increased to nearly 15 months from 13–14 months two weeks ago, and the company is seeing higher conversion orders. This should provide Top Glove the power to raise its ASP. The company now plans to increase the ASP for August order deliveries higher than initial guidance of 15%. As such, MQ Research is increasing its FY20E/FY21E/FY22E ASP assumptions 3%/57%/4% to factor in both higher ASP increases and spot order allocation.
Lowering target PE on supernormal FY21E earnings. Based on the aforementioned strategy, MQ Research is projecting that FY21E’s net profit will be triple FY20E net profit. Given MQ Research’s belief that FY21E will be the peak of strong earnings that are unlikely to be repeated in following years, MQ Research is lowering its target price-earnings ratio (PER) to 23x (+0.5 SD) from 40x. To cross check the long-term fair value of the stock, MQ Research uses a discounted cash flow (DCF) methodology to derive a fair value of RM18.70, which translates to 10x FY21E/56x FY22E PERs. MQ Research views gloves as a staple within the healthcare industry and that the shares should trade at a premium multiple long term.

freetospeak dalpinia based on 2009, QR announced on 10th July, then it shot up 50% after QR in around 10 days, and then next next QR lagi up another 50%.....then bonus issued, up another 50%

it shot up50% becoz profit growth is about 30% ,and 60% for the subsequent qtrs.

so its the same for qtr 3, (250%) 1.8 to 4.5, so now if qtr 4 is another 300% it will be 13.50.
If qtr 1 profit is 150% then it will be 20.00 and so on.

Thanks for the sharing!!!

Covid19 is 10 times more serious than H1N1......can we expect 50% x 10 times as the margin now is 10 times higher than H1N1

based on 2009, QR announced on 10th July, then it shot up 50% after QR in around 10 days, and then next next QR lagi up another 50%.....then bonus issued, up another 50%

blk A revenue would be counted in next QR, i believe they will use it to produce those spot order which has the highest margin, this is very sure. Means extra 2.2b pieces of glove for next QR for pure spot orders. Wau, the PAT must shot up!!!

freetospeak blk A is using now , blk b not yet...

Thanks for the info

Plant 12 consists of Block A and Block B, each consisting of 8 double former lines with 2.2b pieces each (total 4.4b pieces). As of now, for Block A, its remaining 3 lines started commissioning in end March 2020 on top of the 5 lines already in commercial production. For Block B, all 8 lines are expected to be fully commissioned by 2H 2020. Upon full commercial production by 2H 2020, installed capacity will rise 13.4% to 26.2b pieces per annum.

Is anyone know their Plant 12 ready for production right now?

https://www.worldometers.info/coronavirus/#countries

USA & many countries break record high of covid, demand over supply. Glove can last 3-5 yrs. As after virus, more segments need gloves, not only doctors, nurses & etc.

During H1N1, supermx announced QR on 10 Jul 2009.
If follow this date, next Friday is 10 July 2020 may announce QR

All of us must remember before MCO, Harta price is leading Topglov about RM1-2, so it deserve at least RM18-19 right now if Topglove is RM17